DDInter1042 DDInter893
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.** Hydroxychloroquine was granted FDA approval on 18 April 1955. A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.
Hydroxychloroquine {u} (Compound) resembles {v} (Compound) Chloroquine
Hydroxychloroquine {u} (Compound) resembles {v} (Compound) Amodiaquine
Hydroxychloroquine {u} may lead to a major life threatening interaction when taken with {v} Primaquine
Hydroxychloroquine {u} (Compound) binds {v} (Gene) TLR9
Hydroxychloroquine {u} (Compound) upregulates {v} (Gene) PAK1
Hydroxychloroquine {u} (Compound) downregulates {v} (Gene) TES
Hydroxychloroquine {u} (Compound) causes {v} (Side Effect) Vomiting
Hydroxychloroquine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Hydroxychloroquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Hydroxychloroquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Iodide I-131
Hydroxychloroquine (Compound) resembles Chloroquine (Compound)
Hydroxychloroquine (Compound) resembles Amodiaquine (Compound)
Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Hydroxychloroquine (Compound) binds TLR9 (Gene)
Hydroxychloroquine (Compound) upregulates PAK1 (Gene)
Hydroxychloroquine (Compound) downregulates TES (Gene)
Hydroxychloroquine (Compound) causes Vomiting (Side Effect)
Hydroxychloroquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131